Skip to content
diphenylpyraline

Structure via PubChem · Public domain (PubChem)

EntityQ411150· pop 11· linked from 1,089 articles

diphenylpyraline

Sign in to save

Also known as diphenylpyralamine, 4-(benzhydryloxy)-N-methylpiperidine, 1-methyl-4-hydroxypiperidine benzhydryl ether, 4-(benzhydryloxy)-1-methylpiperidine, 1-methyl-4-piperidyl benzhydryl ether

Diphenylpyraline (DPP; sold as Allergen, Arbid, Belfene, Diafen, Hispril, Histyn, Lergobine, Lyssipol, Mepiben, Neargal) is a first-generation antihistamine with anticholinergic effects of the diphenylpiperidine class. It is marketed in Europe for the treatment of allergies. DPP has also been found to act as a dopamine reuptake inhibitor and produces hyperactivity in rodents. It has been shown to be useful in the treatment of Parkinsonism.

Chemical data

Formula
C19H23NO
Molecular weight
281.4 g/mol
IUPAC name
4-benzhydryloxy-1-methylpiperidine

via PubChem

Drug data · ChEMBL

Max clinical phase
Approved
Molecule type
Small molecule
First approval
1982
Admin. routes
oral
Indications
allergic disease

via ChEMBL · EBI

Wikidata facts

Mass
281.178
Has use
medication
Show 5 more facts
chemical formula
C₁₉H₂₃NO
canonical SMILES
CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3
World Health Organisation international non-proprietary name
diphenylpyraline
defined daily dose
10.0
Commons category
Diphenylpyraline
Sources (3)

via Wikidata · CC0

~1 min read

Encyclopedic overview

3 sections
Contents
  • Synthesis
  • See also
  • References

Diphenylpyraline (DPP; sold as Allergen, Arbid, Belfene, Diafen, Hispril, Histyn, Lergobine, Lyssipol, Mepiben, Neargal) is a first-generation antihistamine with anticholinergic effects of the diphenylpiperidine class. It is marketed in Europe for the treatment of allergies. DPP has also been found to act as a dopamine reuptake inhibitor and produces hyperactivity in rodents. It has been shown to be useful in the treatment of Parkinsonism.

==Synthesis== 501px|center|class=skin-invert-image

Excerpted from Wikipedia’s “diphenylpyraline” article, available under the CC BY-SA 4.0 licence.

Gallery (2)